Severe mandibular osteomyelitis and exfoliation of a mandibular canine tooth in a Vietnamese potbellied pig

Smith, Joe S.; Griffin, Caroline; Jones, Phil; Mulherin, Brenda L.; Hecht, Silke

doi:10.1002/vrc2.348

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Production and miniature companion pigs undergo many surgical procedures where inhibition of emesis would be beneficial for patient management (Anderson & Mulon, 2019; Smith & Seddighi, 2022). Miniature companion pigs are increasing in popularity as pets (Curnutte, 2014) and as such, will undergo anesthesia for routine procedures such as ovariohysterectomies (Cypher et al, 2017), tusk and hoof maintenance (Smith, Griffin, et al, 2022; Smith & Seddighi, 2022), as well as non‐routine procedures such as gastrointestinal (Cain et al, 2020; Ehrle et al, 2019), urinary (Needleman & Videla, 2019), or orthopedic surgeries (Høy‐Petersen et al, 2020; Smith et al, 2017). In addition, pigs will occasionally present to veterinarians for vomiting, and a paucity of information regarding the use of maropitant in pigs, including pharmacokinetics, currently exists.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of intramuscular maropitant in pigs (Sus scrofa domesticus)

Smith

Gebert

Ebner

et al. 2023

Vet Pharm & Therapeutics

Self Cite

View full text Add to dashboard Cite

Pigs are at risk of vomiting from medical conditions as well as the emetic side effects of drugs administered for peri‐operative manipulations, but there is a lack of pharmacokinetic data for potential anti‐emetic therapies, such as maropitant, in this species. The main objective of this study was to estimate plasma pharmacokinetic parameters for maropitant in pigs after a single intramuscular (IM) administration dosed at 1.0 mg/kg. A secondary objective was to estimate pilot pharmacokinetic parameters in pigs after oral (PO) administration at 2.0 mg/kg. Maropitant was administered to six commercial pigs at a dose of 1.0 mg/kg IM. Plasma samples were collected over 72 h. After a 7‐day washout period, two pigs were administered maropitant at a dose of 2.0 mg/kg PO. Maropitant concentrations were measured via liquid chromatography/mass spectrometry (LC–MS/MS). A non‐compartmental analysis was used to derive pharmacokinetics parameters. No adverse events were noted in any of the study pigs after administration. Following single IM administration, maximum plasma concentration was estimated at 412.7 ± 132.0 ng/mL and time to maximum concentration ranged from 0.083 to 1.0 h. Elimination half‐life was estimated at 6.7 ± 1.28 h, and mean residence time was 6.1 ± 1.2 h. Volume of distribution after IM administration was 15.9 L/kg. Area under the curve was 1336 ± 132.0 h*ng/mL. The relative bioavailability of PO administration was noted to be 15.5% and 27.2% in the two pilot pigs. The maximum systemic concentration observed in the study pigs after IM administration was higher than what was observed after subcutaneous administration in dogs, cats, or rabbits. The achieved maximum concentration exceeded the concentrations for anti‐emetic purposes in dogs and cats; however, a specific anti‐emetic concentration is currently not known for pigs. Further research is needed into the pharmacodynamics of maropitant in pigs to determine specific therapeutic strategies for this drug.

show abstract